Dec. 21 at 5:14 PM
$CDXS My research indicates there two enzymatic ligation synthetis; Alnylam siRELIS and Codexis ECO.
The rest of the industry of both siRNA drugs developpers (Novartis, Novo Nordisk, Eli Lilly and recently Alnylam) plus CDMO (Bachem, Nitto Avecia, Agilent, Merck and ST Pharma) are using the traditional solid phase oligonucleotide synthesis (SPOS) technology.
siRELIS is more a proprietary technology by Alnylam that uses enzymatic ligation to join short, high quality RNA “blockmers” into final siRNA. It focuses on reducing use of starting materials, organic solvents, and plant time while maintaining Alnylam’s existing siRNA chemistries and quality attributes.
ECO is more like universal platform to adopt or license to build next gen enzymatic ligation across multiple siRNA programmes. Benefits of scalability, efficiency, eco friendlt and cost saving.
